《2011年欧洲抗风湿联盟银屑病关节炎药物治疗建议》解读及思考
被引量:3
摘要
银屑病关节炎(psoriatic arthritis,PsA)是与银屑病相关的炎性关节病,其临床表现复杂多样。它不但有多种关节病变表型,还可有多种关节外表现,包括皮肤、指甲病变及指(趾)炎和附着点炎。目前临床上对PsA的治疗尚未形成理论体系,临床上如何规范、有效地治疗PsA是风湿科医生所面临的问题。近期,欧洲抗风湿联盟(EULAR)组织了来自欧洲和美国的多名风湿病学家以及其他相关学科专家组成银屑病和银屑病关节炎研究组(GRAPPA)
出处
《中华风湿病学杂志》
CAS
CSCD
北大核心
2013年第1期63-64,共2页
Chinese Journal of Rheumatology
参考文献15
-
1Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis, 2012, 71: 4-12.
-
2Gottlieb A, Korman N J, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol, 2008, 58: 851-864.
-
3Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis, 2009, 68:1387-1394.
-
4Black RL, O'Brien WM, Vanscott EJ, et al. Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA, 1964, 189: 743-747.
-
5Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum, 1984, 27: 376-381.
-
6Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol, 2009, 60: 824-837.
-
7Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a department of veterans affairs cooperative study. Arthritis Rheum, 1996, 39: 2013-2020.
-
8Nash PD, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology, 2006, 212: 238- 249.
-
9Fraser AD, van Kttijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trim of combina- tion therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis, 2005, 64: 859-864.
-
10Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis, 2009, 68: 702-709.
同被引文献42
-
1Maeda S, Hayami Y, Naniwa T,et al. The Th17/IL23 axis and natu- ral immunity in psoriatic arthritis[ J]. Inter J Rheum,2012( 1 ) :1- 8.
-
2Wang M,Shen J, Jin H, et al. Recent progress in understanding mo- lecular mechanisms of cartilage degeneration dtlring osteoarthritis [J]. Ann N Y Acad Sci,2011,12(40) :61-69.
-
3Mease PJ. Spondyloarthritis: Is msthotrexate effective in psoriatic ar- thritis[J]. Nat Rev Rheumatol,2012,8(5) :251-252.
-
4Ghazizadeh R,Tosa M, Ghazizadeh M, Clinical improvement in pso- riasis with treatment of associated hyperlipidemia [ J ]. Am JM ed Sci ,2011,341 (5) :394-398.
-
5Mease P. Update on treatment of psoriatic arthritis [ J ]. Bull NYU Hosp Jt Dis,2012,70 (3) : 167-171.
-
6Mumeaz A, Fite Gerald O. Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice [J]. Curr Rheumatol Rep, 2010, 12(4) : 264- 271.
-
7Gotnjeb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthri- tis : section 2. Psoriatic arthritis : overview and guidelines of care for treatment with an emphasis on the biologics[ J]. J Am Acad Dermatol, 2008,58 ( 5 ) : 851-864.
-
8Mease PJ. Psoriatic arthritis: pharmacotherapy update [ J]. Curr Rheumatol Rep,2010,12(4) :272-280.
-
9Helliwell PS, Taylor WJ, CASPAR study Group. Treat- ment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs-comparison of drugs and adverse reactions [ J ]. J Rheumato1,2008,35 ( 3 ) :472-476.
-
10Striesow F, Brandt A. Preference, satisfaction and usabili- ty of subcutaneously administered methotrexate for rheu- matoid arthritis or psoriatic arthritis: results of a postmar- keting surveillance study with a high-concentration formu- lation[J]. Ther Adv Musculoskelet Dis, 2012,4( 1 ) :3-9.
引证文献3
-
1温丽英,朱由瑾,冯冬梅.类风湿因子、C反应蛋白、抗链O在银屑病关节炎中的检测及意义[J].中国临床医生杂志,2015,43(6):56-57. 被引量:1
-
2戈旦,闵仲生,郭顺.银屑病关节炎的药物治疗现状[J].皮肤性病诊疗学杂志,2016,23(2):136-138. 被引量:4
-
3龚小芳,杨婷,何成松,冯碧敏,叶云,邹榆红,王国俊.Apremilast不同用药方案治疗银屑病关节炎的疗效和安全性的系统评价[J].中国药房,2018,29(21):2985-2991. 被引量:2
二级引证文献7
-
1江艳,郭妙兰,邱晓瑜.寻常型银屑病患者自我感受负担的现状与影响因素[J].皮肤性病诊疗学杂志,2017,24(5):331-334. 被引量:5
-
2史修波,佘冬华,兰小琼.来氟米特联合甲氨蝶呤治疗银屑病关节炎皮肤病变的效果分析[J].中国基层医药,2018,25(4):503-506. 被引量:1
-
3徐辉,邓玲,李学荣.托珠单抗治疗活动性难治性类风湿关节炎的疗效及不良反应[J].中国医刊,2019,54(4):425-427. 被引量:12
-
4唐静,黎艳红,张秋平,何成松,刘毅.IL-17A拮抗剂对银屑病关节炎的疗效和安全性的系统评价[J].中国新药杂志,2020(10):1187-1194. 被引量:2
-
5吕姗,赖小丽,刘娜.以达标理论为指导的信息化延续性护理对银屑病患者依从性及自我健康管理能力的影响[J].齐鲁护理杂志,2022,28(17):74-77. 被引量:8
-
6江薇,帅宏.银屑病患者药物治疗依从性的相关危险因素分析[J].罕少疾病杂志,2023,30(12):81-82. 被引量:1
-
7王凯,王建峰,欧阳雪晴,何中秋.中医药在关节病型银屑病治疗中的应用[J].世界最新医学信息文摘,2018,0(62):62-63. 被引量:1
-
1尹静.银屑病关节炎23例护理体会[J].基层医学论坛,2011,15(12):377-378. 被引量:1
-
2邓雪蓉,张卓莉.银屑病和银屑病关节炎研究评价组发布2015银屑病关节炎治疗建议[J].中华风湿病学杂志,2016,20(9):646-648. 被引量:4
-
3吴新宇,叶华.欧洲抗风湿病联盟关于银屑病关节炎药物治疗十项建议[J].中华风湿病学杂志,2011,15(12):838-838. 被引量:1
-
4李珊珊,苏茵.西班牙关于皮肤科医师与风湿科医师协同治疗银屑病关节炎的建议[J].中华风湿病学杂志,2014,18(2):140-141. 被引量:2
-
5屈丽娜,王广进,亓兴亮,田洪青,蒋红伟,张福仁.表现为外周附着点炎的关节病型银屑病2例[J].中国麻风皮肤病杂志,2010,26(2):129-130.
-
6何坚,忻霞菲,陈勇.银屑病关节炎32例临床分析[J].浙江医学,2005,27(4):297-298.
-
7李丹.两种联合疗法治疗尖锐湿疣170例临床研究[J].中国医药科学,2012,2(24):217-218. 被引量:6
-
8安媛,吕玲.银屑病关节炎治疗的推荐意见[J].中华风湿病学杂志,2009,13(12):863-863. 被引量:4
-
9谈善庆,李竹青.SLE并发周围神经炎一例[J].中国皮肤性病学杂志,1989(1):45-45.
-
10FDA批准治疗活动性银屑病性关节炎药物Apremilast上市[J].中国执业药师,2014(6):38-38.